AG
TRML

Artal Group’s Tourmaline Bio TRML Stock Holding History

Artal Group’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-91,426
Closed -$1.18M – 91
2024
Q2 		$1.18M Sell
91,426
-223,070
-71% -$3.59M 0.03% 87
2024
Q1 		$7.2M Buy
314,496
+223,070
+244% +$7.87M 0.18% 53
2023
Q4 		$2.39M Hold
91,426
– – 0.08% 63
2023
Q3 		$2.57M Hold
91,426
– – 0.11% 65
2023
Q2 		$2.78M Hold
91,426
– – 0.09% 77
2023
Q1 		$1.72M Sell
91,426
-115,000
-56% -$1.9M 0.1% 83
2022
Q4 		$2.11M Hold
206,426
– – 0.12% 86
2022
Q3 		$5.43M Hold
206,426
– – 0.23% 57
2022
Q2 		$9.31M Hold
206,426
– – 0.5% 40
2022
Q1 		$20.3M Hold
206,426
– – 0.85% 28
2021
Q4 		$31.6M Hold
206,426
– – 0.86% 30
2021
Q3 		$28M Hold
206,426
– – 0.63% 36
2021
Q2 		$30.3M Buy
+206,426
New +$31.6M 0.62% 36

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Artal Group's TRML Position: Q3 2024 in Review

Artal Group sold out of Tourmaline Bio (TRML) in Q3 2024, closing a stake of 91,426 shares — an estimated $1.18M sold.

Artal Group first reported a position in TRML in Q2 2021 and held it in 13 quarters. The position peaked at $31.6M in Q4 2021. 92 funds tracked by Wall St. Rank hold TRML as of Q3 2024.

  • Artal Group reported no remaining Tourmaline Bio position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 91,426 Tourmaline Bio shares in Q3 2024, an estimated $1.18M.
  • Artal Group first reported a position in Tourmaline Bio in Q2 2021 and held it in 13 quarters.
  • Artal Group's Tourmaline Bio position peaked at $31.6M in Q4 2021.
  • 92 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.